The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
New insights on oncologist use of genomic testing.
 
Mary Lou Smith
Consulting or Advisory Role - Bayer (Inst); Novartis; Pfizer
Research Funding - Exact Sciences (Inst); Foundation Medicine (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Seagan (Inst)
 
Carol B. White
Research Funding - Genentech (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst)
 
Elda Railey
Employment - Advanced Pharmacy (I)
Research Funding - Daiichi Sankyo/UCB Japan (Inst); Exact Sciences (Inst); Foundation Medicine (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PreludeDx (Inst); Seagen (Inst)
 
Stacy W. Gray
Stock and Other Ownership Interests - Magenta Therapeutics (I)
 
David E Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - BeiGene; Catalyst Pharmaceuticals; Daichi Sankyo; Janssen Oncology; Mirati Therapeutics; Regeneron; Sanofi
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Karyopharm Therapeutics (Inst); Novocure (Inst)
Patents, Royalties, Other Intellectual Property - Co-founder, Chief Scientific Officer, OncoSeer Diagnostics, LLC; Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.; UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 3352 - US Patent Application 17/045,482 PREDICTION AND TREATMENT OF IMMUNOTHERAPEUTIC TOXICITY (“Chemokines” and “Cytokines”); UTSD 4153 - US Patent Application 63/386,387 IMMUNOTHERAPY TOXICITY – CELL PHENOTYPES; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4169 - US Patent Application 63/382,972 BIOMARKERS INCLUDING RNA FOR IMMUNOTHERAPY TOXICITY; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS; UTSD 4184 - US Patent Application 63/382,257 T CELL TOLERANT FRACTION AS A PREDICTOR OF IMMUNE-RELATED ADVERSE EVENTS
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb